3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 29 points (-0.2%) at 17,702 as of Tuesday, Nov. 10, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,315 issues advancing vs. 1,646 declining with 122 unchanged.

The Drugs industry currently sits down 0.8% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include

Dr Reddy Laboratories

(

RDY

), down 11.8%,

Halozyme Therapeutics

(

HALO

), down 11.0%,

Anacor Pharmaceuticals

(

ANAC

), down 6.2%,

Mallinckrodt

(

MNK

), down 6.0% and

Jazz Pharmaceuticals

(

JAZZ

), down 4.3%. Top gainers within the industry include

Intercept Pharmaceuticals

(

ICPT

), up 10.3%,

Opko Health

(

OPK

), up 5.0% and

Gilead

(

GILD

), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Teva Pharmaceutical Industries

(

TEVA

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Teva Pharmaceutical Industries is down $0.50 (-0.8%) to $59.27 on light volume. Thus far, 895,842 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.0 million shares. The stock has ranged in price between $59.17-$60.10 after having opened the day at $59.45 as compared to the previous trading day's close of $59.77.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $51.3 billion and is part of the health care sector. Shares are up 3.9% year-to-date as of the close of trading on Monday. Currently there are 12 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Teva Pharmaceutical Industries

as a

buy

. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Teva Pharmaceutical Industries Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Regeneron Pharmaceuticals

(

REGN

) is down $3.48 (-0.6%) to $555.04 on light volume. Thus far, 191,535 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 921,100 shares. The stock has ranged in price between $553.48-$561.60 after having opened the day at $559.00 as compared to the previous trading day's close of $558.52.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $57.4 billion and is part of the health care sector. Shares are up 36.1% year-to-date as of the close of trading on Monday. Currently there are 8 analysts that rate Regeneron Pharmaceuticals a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Regeneron Pharmaceuticals

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Regeneron Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Valeant Pharmaceuticals International

(

VRX

) is down $6.03 (-7.1%) to $79.38 on heavy volume. Thus far, 11.1 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 10.1 million shares. The stock has ranged in price between $79.01-$86.40 after having opened the day at $84.76 as compared to the previous trading day's close of $85.41.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $28.1 billion and is part of the health care sector. Shares are down 40.3% year-to-date as of the close of trading on Monday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Valeant Pharmaceuticals International

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and generally higher debt management risk. Get the full

Valeant Pharmaceuticals International Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...